Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 115

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 2
Chunk 115
---
 which we believe demonstrates successful pan-cancer implementation of whole genome sequencing (WGS)-based personalized circulating tumor DNA, or ctDNA, detection. In more than 100 patients, the interim results of this study show 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess, detection of tumor fractions as low as 0.0001%, and a lead time in detecting recurrence compared to imaging. We believe this data demonstrates the potential importance of our ultra-sensitive Precise MRD test compared to first-generation MRD tests.

Results of Operations for the Three Months Ended June 30, 2025 and 2024

The results of operations for the three months ended June 30, 2025 and 2024 are discussed below.  

Revenue

The following table summarizes year-over-year revenue changes in our core product categories:

Three months ended June 30,% of Total Revenue(in millions)20252024Change20252024Hereditary Cancer$96.3 $91.5 $4.8 45%44%Tumor Profiling31.4 32.6 (1.2)15%15%Prenatal47.6 44.4 3.2 22%21%Pharmacogenomics37.8 43.0 (5.2)18%20%Total revenue$213.1 $211.5 $1.6 100%100%

The following table summarizes volume changes in our core product categories:

Three months ended June 30,(in thousands)20252024% ChangeVolume:Hereditary Cancer78 73 7 %Tumor Profiling12 14 (14)%Prenatal159 173 (8)%Pharmacogenomics135 129 5 %Total384 389 (1)%

Revenues increased $1.6 million for the three months ended June 30, 2025 compared to the same period in the prior year primarily due to an increase in the average revenue per test, due in part to changes in contracted price and operational improvements, which was partially offset by a 1% decrease in volume. Hereditary Cancer revenues increased $4.8 million for the three months ended June 30, 2025 compared to the same period in the prior year primarily due to a 7% increase in  volume. Prenatal revenues increased $3.2 million for the three months ended June 30, 2025 compared